DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 18-613/S-011

Medicis Pharmaceutical Corporation
Attention: Mitchell S. Wortzman, Ph.D.
Executive Vice President
Research and Development
8125 North Hayden Road
Scottsdale, Arizona 85258-2463

Dear Dr. Wortzman:

Please refer to your new supplemental drug application dated December 6, 2002, received December 9, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for OVIDE (malathion) Lotion, 0.5%.

We also acknowledge your correspondence dated March 31, 2003.

This supplemental new drug application provided revised wording to the Carcinogenesis, Mutagenesis, and Impairment of Fertility section of the label as requested in the Agency's letter dated, November 8, 2002.

We have completed the review of this application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed final printed labeling text. Accordingly, this application is approved effective on the date of this letter.

However, during review of the submission, it was noted that:

1. In the **Carcinogenesis, Mutagenesis, and Impairment of Fertility** section of the label, the dose multiples that normalize the body surface area for the fertility studies appear to be calculated based on a (b)(4)----------of OVIDE Lotion, not a 60 kg adult using 10 mg of Ovide Lotion, as should be the case.
2. In the **Pregnancy** section of the label, the dose multiples that normalize for body surface area appear to be calculated based on a (b)(4)---------- of OVIDE Lotion, not a 60 kg adult using 10 ml of Ovide Lotion, as should be the case.

Therefore at the next printing, we request that the following changes be made to the OVIDE Lotion package insert.

The last paragraph of the **Carcinogenesis, Mutagenesis, and Impairment of Fertility** section of the label should read:

"Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility."

The third sentence in the **Pregnancy** section should read:

"These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability)."

The above requested changes may be reported in your next annual report to your NDA.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Millie Wright, Project Manager, at (301) 827-2020.

Sincerely,

Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic and Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

John Kelsey
4/4/03 03:58:18 PM
for Dr. Wilkin